Having shown that ApoA‐IV serum levels decrease during allergic inflammation and that supplementation with ApoA‐IV prevents the influx of eosinophils into the airways, we further assessed the impact of ApoA‐IV on airway hyperresponsiveness. This evidence concerns the gene APOA4 and airway hyperresponsiveness.